Omnicell, Inc. (NASDAQ: OMCL) is a Healthcare company (Medical - Healthcare Information Services) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
Omnicell, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $34.00, Omnicell, Inc. trades at 35.0x trailing earnings, 1.3x sales and 1.2x book value, with an EV/EBITDA of 9.7. Over the last twelve months it generated about $1.2B of revenue and $45M of net income. It runs a gross margin of 45.1%, an operating margin of 5.3% and a net margin of 3.6%. It shows return on equity of 3.5%, return on invested capital of 2.7% and a free cash flow yield of 9.2%. On the balance sheet: a debt-to-equity ratio of 0.15 and a current ratio of 1.66. Over the past 52 weeks the share price ranged from $31.75 to $55.00, with a beta of 0.89.
Omnicell, Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 10 Buy and 10 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, Omnicell, Inc. (OMCL) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 10.6% / 30% · (Cash+Inv) / Mkt Cap (36m) 19.7% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 10.6% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 19.7% / 33% · Receivables / Mkt Cap (36m) 14.8% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 10.6% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 19.7% / 33.33% · Receivables / Mkt Cap (24m) 14.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 8.37% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 13.5% / 33.33% · Receivables / Avg Assets (4Q) 11.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 8.19% / 33.33% · (Cash+ST Inv) / Total Assets 15.3% / 33.33% · (Cash+Recv) / Total Assets 26.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
Yes. As of September 2026, Omnicell, Inc. (OMCL) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Omnicell, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Omnicell, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.